Clinical Trials · NCT03496298

Effect of Efpeglenatide on Cardiovascular Outcomes

Name: Effect of Efpeglenatide on Cardiovascular Outcomes
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Efpeglenatide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Sanofi
Enrollment: 4,076
Start date: Apr 2018
Locations: 353 sites, 28 countries
Primary endpoint: Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority Analysis

View Efpeglenatide compound reference